{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-056320","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.964490+00:00","generated_at":"2026-06-15T16:28:44.138205+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunome reports Q1 2023 net loss of $4.3M; posts $2.4M collaboration revenue from AbbVie deal","bullets":["Collaboration revenue of $2.4M from AbbVie strategic deal for up to 10 novel antibody-target pairs.","Net loss of $4.3M for Q1 2023; R&D expenses $3.9M, G&A expenses $2.8M.","Cash and cash equivalents $44.4M as of March 31, 2023.","AbbVie deal includes $30M upfront, $70M platform milestones, and up to $120M per target in development/commercial milestones.","Formed Antibody-Drug Conjugate and T Cell Redirection Advisory Board in February 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-056320","json":"https://secwatch.observer/filing/0001104659-23-056320.json","markdown":"https://secwatch.observer/filing/0001104659-23-056320.md","text":"https://secwatch.observer/filing/0001104659-23-056320.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923056320/0001104659-23-056320-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923056320/tm2314520d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T16:28:44.138205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"70b05950dd62d3bdbde11af77444c35750f70fe5","claim":"Immunome Inc. reported the first quarter ended March 31, 2023 results: revenue $2.4 million, net income $4.3 million.","evidence_excerpt":"including ADCs. Financial Highlights · Collaboration Revenue : Collaboration Revenue from the Collaboration Agreement with AbbVie for the three months ended March 31, 2023 was $2.4 million. · Research and development (R&D) expenses: R&D expenses for the three months ended March 31, 2023 were $3.9 million. · General and administrative (G&A) expenses: G&A expenses,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923056320/0001104659-23-056320-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$2.4 million"},{"label":"Net income","value":"$4.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}